Anonymous Biopharmaceutical Pioneer

For over 15 years, this biopharmaceutical company's Process Development division—responsible for scaling R&D therapeutics to clinical-trial batches—accumulated more than 2 million paper batch records, requiring a dedicated storage room. In FDA-regulated pharmaceutical manufacturing, paper-based batch records create significant compliance risk: transcription errors, missed signatures, and out-of-order production steps can invalidate batches or trigger regulatory findings. Manual quality review happened after production rather than in real time, limiting the company's ability to catch deviations before they cascaded into batch failures. With a pipeline of over a dozen investigational therapeutics in active clinical development, the cost of inefficient batch cycles and poor data accessibility was becoming a direct constraint on R&D throughput.

Following a competitive evaluation, the Process Development division selected Rockwell Automation's FactoryTalk PharmaSuite—a Manufacturing Execution System (MES) purpose-built for life sciences—to digitize its batch record process. This deployment was notably the first time PharmaSuite had been implemented in a Process Development (rather than GMP production) context, and the company's first MES adoption of any kind. Rockwell Automation's strategic account team collaborated closely with both the IT and business teams throughout configuration, implementing 10 complex recipes and system extensions. The implementation ran concurrently with active batch production, with Rockwell Automation providing hands-on support to ensure continuity. The project completed in 2023 and is positioned as the first phase of a broader digital transformation that will eventually integrate MES with ERP and data management platforms.

The PharmaSuite implementation delivered measurable improvements across cycle time, throughput, and compliance overhead:

• Batch cycle time reduced from 10 weeks to 8 weeks per batch
• Annual batch production increased by approximately 2 additional batches per year
• Paper eliminated: ~500 pages per product campaign, equating to over 3,000 pages annually
• Batch record report generation reduced from several days of manual effort to minutes—completed at end-of-batch with a single button press

Beyond the headline numbers, parallel processing now allows multiple users to work within the system simultaneously—something paper workflows cannot support. Real-time quality verification enables deviations to be identified and corrected within the active batch rather than discovered post-production.

• Start digital transformation where variance is highest: deploying MES in Process Development—not GMP production—let the team build competency in a lower-risk environment before scaling to regulated manufacturing.
• Business ownership of system configuration is non-negotiable: involving process owners in every configuration decision accelerates change management and reduces post-go-live friction.
• Real-time verification changes the economics of batch failures: catching deviations during production rather than after eliminates rework costs that compound across clinical programs.
• Concurrent deployment is viable with the right vendor support: running implementation alongside active batch production is feasible when the implementation partner provides continuous, responsive coverage.
• Electronic records unlock analytics that paper never could: the same data used for compliance becomes the foundation for predictive batch analytics.